These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 28624167)

  • 1. Longitudinal Vision-Related Quality of Life for Patients with Noninfectious Uveitis Treated with Fluocinolone Acetonide Implant or Systemic Corticosteroid Therapy.
    Sugar EA; Venugopal V; Thorne JE; Frick KD; Holland GN; Wang RC; Almanzor R; Jabs DA; Holbrook JT;
    Ophthalmology; 2017 Nov; 124(11):1662-1669. PubMed ID: 28624167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality of Life and Risks Associated with Systemic Anti-inflammatory Therapy versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, or Panuveitis: Fifty-four-Month Results of the Multicenter Uveitis Steroid Treatment Trial and Follow-up Study.
    Multicenter Uveitis Steroid Treatment (MUST) Trial Follow-up Study Research Group
    Ophthalmology; 2015 Oct; 122(10):1976-86. PubMed ID: 26298718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial.
    ; Kempen JH; Altaweel MM; Holbrook JT; Jabs DA; Louis TA; Sugar EA; Thorne JE
    Ophthalmology; 2011 Oct; 118(10):1916-26. PubMed ID: 21840602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benefits of Systemic Anti-inflammatory Therapy versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, and Panuveitis: Fifty-four-Month Results of the Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study.
    ; Kempen JH; Altaweel MM; Drye LT; Holbrook JT; Jabs DA; Sugar EA; Thorne JE
    Ophthalmology; 2015 Oct; 122(10):1967-75. PubMed ID: 26298715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Adalimumab on Visual Functioning in Patients With Noninfectious Intermediate Uveitis, Posterior Uveitis, and Panuveitis in the VISUAL-1 and VISUAL-2 Trials.
    Sheppard J; Joshi A; Betts KA; Hudgens S; Tari S; Chen N; Skup M; Dick AD
    JAMA Ophthalmol; 2017 Jun; 135(6):511-518. PubMed ID: 28426849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Responsiveness of Vision-Specific and General Quality of Life Metrics to Ocular and Systemic Events in Patients with Uveitis.
    Sugar EA; Burke AE; Venugopal V; Thorne JE; Holbrook JT;
    Ophthalmology; 2020 Dec; 127(12):1710-1718. PubMed ID: 32717341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Injectable Fluocinolone Acetonide Long-Acting Implant for Noninfectious Intermediate Uveitis, Posterior Uveitis, and Panuveitis: Two-Year Results.
    Jaffe GJ; Lin P; Keenan RT; Ashton P; Skalak C; Stinnett SS
    Ophthalmology; 2016 Sep; 123(9):1940-8. PubMed ID: 27421623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association Between Long-Lasting Intravitreous Fluocinolone Acetonide Implant vs Systemic Anti-inflammatory Therapy and Visual Acuity at 7 Years Among Patients With Intermediate, Posterior, or Panuveitis.
    ; Kempen JH; Altaweel MM; Holbrook JT; Sugar EA; Thorne JE; Jabs DA
    JAMA; 2017 May; 317(19):1993-2005. PubMed ID: 28477440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence and Outcome of Uveitic Glaucoma in Eyes With Intermediate, Posterior, or Panuveitis Followed up to 10 Years After Randomization to Fluocinolone Acetonide Implant or Systemic Therapy.
    Kempen JH; Van Natta ML; Friedman DS; Altaweel MM; Ansari H; Dunn JP; Elner SG; Holbrook JT; Lim LL; Sugar EA; Jabs DA;
    Am J Ophthalmol; 2020 Nov; 219():303-316. PubMed ID: 32628922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of fluocinolone acetonide implant versus systemic therapy for noninfectious intermediate, posterior, and panuveitis.
    ; Sugar EA; Holbrook JT; Kempen JH; Burke AE; Drye LT; Thorne JE; Louis TA; Jabs DA; Altaweel MM; Frick KD
    Ophthalmology; 2014 Oct; 121(10):1855-62. PubMed ID: 24908205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health- and Vision-Related Quality of Life in a Randomized Controlled Trial Comparing Methotrexate and Mycophenolate Mofetil for Uveitis.
    Kelly NK; Chattopadhyay A; Rathinam SR; Gonzales JA; Thundikandy R; Kanakath A; Murugan SB; Vedhanayaki R; Cugley D; Lim LL; Suhler EB; Al-Dhibi HA; Ebert CD; Berlinberg EJ; Porco TC; Acharya NR;
    Ophthalmology; 2021 Sep; 128(9):1337-1345. PubMed ID: 33675850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Normative comparison of patient-reported outcomes in patients with noninfectious uveitis.
    Naik RK; Rentz AM; Foster CS; Lightman S; Belfort R; Lowder C; Whitcup SM; Kowalski JW; Revicki DA
    JAMA Ophthalmol; 2013 Feb; 131(2):219-25. PubMed ID: 23411886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Vision-and health-related quality of life in patients with uveitis].
    Zhang J; Yan HG; Chi Y; Guo CY; Yang L
    Zhonghua Yan Ke Za Zhi; 2016 Jun; 52(6):429-36. PubMed ID: 27373571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality-of-Life Outcomes From a Randomized Clinical Trial Comparing Antimetabolites for Intermediate, Posterior, and Panuveitis.
    Niemeyer KM; Gonzales JA; Rathinam SR; Babu M; Thundikandy R; Kanakath A; Porco TC; Browne EN; Rao MM; Acharya NR
    Am J Ophthalmol; 2017 Jul; 179():10-17. PubMed ID: 28414043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time to disease recurrence in noninfectious uveitis following long-acting injectable fluocinolone acetonide implant.
    Cai CX; Skalak C; Keenan RT; Grewal DS; Jaffe GJ
    Graefes Arch Clin Exp Ophthalmol; 2020 May; 258(5):1023-1030. PubMed ID: 32114654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of a Fluocinolone Acetonide Insert on Recurrence Rates in Noninfectious Intermediate, Posterior, or Panuveitis: Three-Year Results.
    Jaffe GJ; Pavesio CE;
    Ophthalmology; 2020 Oct; 127(10):1395-1404. PubMed ID: 32624244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The multicenter uveitis steroid treatment trial: rationale, design, and baseline characteristics.
    ; Kempen JH; Altaweel MM; Holbrook JT; Jabs DA; Sugar EA
    Am J Ophthalmol; 2010 Apr; 149(4):550-561.e10. PubMed ID: 20097325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vision-related functioning outcomes of dexamethasone intravitreal implant in noninfectious intermediate or posterior uveitis.
    Lightman S; Belfort R; Naik RK; Lowder C; Foster CS; Rentz AM; Cui H; Whitcup SM; Kowalski JW; Revicki DA
    Invest Ophthalmol Vis Sci; 2013 Jul; 54(7):4864-70. PubMed ID: 23761087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vision- and health-related quality of life in patients with Behçet uveitis.
    Onal S; Savar F; Akman M; Kazokoglu H
    Arch Ophthalmol; 2010 Oct; 128(10):1265-71. PubMed ID: 20937995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of elevated intraocular pressure and glaucoma in patients with uveitis: results of the multicenter uveitis steroid treatment trial.
    Friedman DS; Holbrook JT; Ansari H; Alexander J; Burke A; Reed SB; Katz J; Thorne JE; Lightman SL; Kempen JH;
    Ophthalmology; 2013 Aug; 120(8):1571-9. PubMed ID: 23601801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.